UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

283516

UV1 Triple Combo Maintenance Therapy Will Be Tested in Phase 2 Trial

Ultimovacs will test its experimental cancer vaccine, UV1, as part of a triple-combination therapy for women with relapsed ovarian cancer who have no mutations in their BRCA DNA repair genes. The Phase 2 DOVACC collaboration study will investigate UV1, in combination with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) and PARP inhibitor Lynparza (olaparib), as a maintenance treatment for women with high-grade ovarian cancer who are responding to their second round of chemotherapy. The trial will…

You must be logged in to read/download the full post.